Journal of Clinical Oncology
Articles in this Issue
Adjuvant chemoradiotherapy versus radiotherapy alone in high-risk endometrial cancer: Updated meta-analysis of randomized trials.
e17635 Background: The survival benefit of adjuvant chemoradiotherapy compared with radiotherapy alone in high-risk endome...
Multilevel disparities in HIV-associated gastrointestinal cancer mortality in the United States, 1999–2020.
e15688 Background: Although gastrointestinal (GI) cancers are more common in people living with HIV (PLWH), it is unclear...
Does a statin a day keep prostate cancer (PC) away?: Statin use and disease progression in patients receiving androgen deprivation therapy (ADT) after radical prostatectomy (RP) in SEARCH.
5091 Background: Prior studies suggest statin use may improve PC outcomes, including PC specific mortality (PCSM) and dise...
Surgical efficacy and complications of cytoreductive surgery with HIPEC for colorectal cancer patients with peritoneal carcinomatosis.
e15549 Background: Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (HIPEC) for colorectal pe...
Malignant Leydig cell tumor: A population-level demographic study using the National Cancer Database.
e17010 Background: Leydig cell tumors (LCTs) are typically rare testicular neoplasms arising from androgen-producing inter...
Effect of dual immune checkpoint inhibitors (ICI) by the time of infusion in advanced non–small cell lung cancer (NSCLC): A secondary analysis of CCTG BR34 trial.
8566 Background: There is increasing evidence suggesting the impact of circadian biology on ICI efficacy in solid tumours,...
Validation of pathology-based triage for the 21-gene recurrence score: A meta-analysis and qualitative synthesis of the Magee equations.
1591 Background: The 21-gene OncotypeDX (ODX) recurrence score (RS) is the standard for chemotherapy decision-making in HR...
Precision histopathologic classification of epithelial ovarian cancer subtypes using a computationally efficient multilayer perceptron framework with global validation.
5605 Background: Epithelial ovarian cancer is the leading cause of gynecologic cancer mortality, with treatment and progno...
Sintilimab in combination with cetuximab and chemotherapy as first-line treatment for microsatellite stable/pMMR and RAS/BRAF wild-type metastatic colorectal cancer (CALLIOPSIS): An open-label, non-comparative, phase Ib/II dose escalation and expansion trial.
e15537 Background: Immunotherapy offers limited therapeutic benefit in microsatellite stable (MSS) metastatic colorectal c...
Staging, surgery, and relapse patterns in uterine sarcomas: A single-institution cohort.
e23553 Background: Uterine sarcomas are rare gynecologic malignancies and are frequently misdiagnosed as benign uterine di...
Forecasting the head and neck cancer burden in Vietnam: Projections from the Hanoi Cancer Registry.
e18075 Background: In Vietnam, head and neck cancers (HNC) represent a growing public health challenge. However, limited l...
Intismeran autogene to induce de novo neoantigen-specific T cells as adjuvant therapy in melanoma.
9564 Background: Intismeran autogene (intismeran) is an individualized mRNA-based neoantigen (neoAg) therapy designed to e...
Response rate of MSI-high/dMMR gastric, esophageal, and gastroesophageal junctional adenocarcinoma to neoadjuvant immunotherapy: A systematic review.
e16134 Background: The success of immunotherapy to treat metastatic microsatellite instability high (MSI-h)/deficient mism...
Primary treatment approaches in advanced HRD-positive (BRCAm and BRCAwt) ovarian cancer in the Russian non-interventional OVARD study.
e17561 Background: Homologous recombination deficiency (HRD) positive status is a clinically meaningful biomarker in ovari...
Long-term survival rates and cure modeling with dostarlimab plus chemotherapy in mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) primary advanced or recurrent endometrial cancer in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial.
5501 Background: Dostarlimab + carboplatin-paclitaxel (CP) demonstrated significant progression-free survival (PFS...
Bridging guidelines and interoperability: mCODE STU4 coverage of NCCN breast cancer decision criteria.
e23188 Background: The minimal Common Oncology Data Elements (mCODE) initiative defines structured data elements using Fas...
Incidence of uveal melanoma surveillance and related outcomes in the immunotherapy era in a rural healthcare system.
e21598 Background: Uveal melanoma has an incidence of 5 cases/million in the United States, with higher incidence among me...
Implementing scalable psychosocial interventions to address patient-identified needs in hereditary cancer syndromes.
e22652 Background: Individuals with hereditary cancer syndromes (HCS), including hereditary breast and ovarian cancer and...
Colorectal cancer risk in cystic fibrosis: Systemic review and quantitative synthesis of epidemiologic, genetic, and clinical evidence.
e15639 Background: Increased survival rates in individuals with cystic fibrosis (CF) have revealed multiple long-term comp...
Deep learning–based imaging models for predicting immune checkpoint inhibitor response in non–small cell lung cancer: A systematic review.
e20582 Background: Imaging-based machine learning models have been widely studied in medicine. Aside from diagnostic model...
Clinical outcomes in older adults with advanced thyroid cancer.
e18012 Background: Age is a prognostic factor in thyroid cancer, with older adults being at higher risk of aggressive hist...
HRS-1167 (M9466), a PARP1 inhibitor, combined with abiraterone acetate and prednisone in metastatic castration-resistant prostate cancer: A phase 1b/2 study.
5036 Background: PARP inhibitors combined with novel hormonal agents (NHAs) have shown improved progression-free survival...
Evaluation of a novel blood-based lung cancer screening test in elevated-risk subjects.
10535 Background: Less than 20% of individuals recommended for lung cancer (LC) screening are screened each year by low do...
Camizestrant plus ribociclib in hormone receptor–positive/HER2-negative advanced breast cancer: The phase II CADILLAC trial.
TPS1150 Background: CDK4/6 inhibitors combined with endocrine therapy (ET) are the standard first-line treatment for hormo...
Effectiveness outcomes by treatment-free interval among patients receiving palbociclib plus endocrine therapy in HR+/HER2− advanced breast cancer in the real-world setting: Results from the PERFORM study.
1061 Background: Combination of CDK4/6 inhibitors (CDK4/6i) plus endocrine therapy (ET) is first-line (1L) standard of car...